MedTrace Logo

Childhood Schistosomiasis: a Novel Strategy Extending the Benefits/Reach of Antihelminthic Treatment

NCT02495909 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 700

Last updated 2018-10-15

No results posted yet for this study

Summary

Objective and Hypotheses: This project has the overall objective of implementing and evaluating new approaches to reducing the current and future burden of urinary schistosomiasis in young children using the antihelminthic drug Praziquantel. The project aims to (1) determine the operational health benefits of treating schistosome infections early on re-infection and morbidity reduction, (2) determine if gut or urine microbiome structure (species diversity or abundance) is a risk factor for S. haematobium infection or morbidity, and (3) elucidate the factors and underlying mechanisms mediating the reduction/reversal of schistosome-related morbidity and resistance against infection/re-infection in young children.

Conditions

  • Schistosomiasis

Sponsors & Collaborators

  • University of Zimbabwe

    collaborator OTHER

  • University of Edinburgh

    lead OTHER

Principal Investigators

  • Francisca Mutapi, PhD · University of Edinburgh

Eligibility

Min Age
3 Years
Max Age
5 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2018-01-31
Completion
2018-02-27

Countries

  • Zimbabwe

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02495909 on ClinicalTrials.gov